1.
Inflamm Bowel Dis
; 28(7): 1130-1133, 2022 07 01.
Article
in English
| MEDLINE | ID: covidwho-1784351
ABSTRACT
T-cell and antibody responses to severe acute respiratory syndrome coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T-cell responses are preserved by most biologic therapies, but augmented by anti-tumor necrosis factor (anti-TNF) treatment. While anti-TNF therapy blunts the antibody response, cellular immunity after vaccination is robust.